About Humanigen
COVID-19
Our Programs
Investor Relations & Media
More
Solebury Trout Talks: Interview with Dale Chappell, Humanigen - Part of the Nametag Series
ASH 2020 ZUMA-19 Poster
The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
Op-Ed: Vaccine race creates blind spots
ZUMA-19 Abstract Accepted for Presentation at ASH 2020 Annual Meeting
Mayo Clinic Proceedings Lenzilumab COVID-19 Case-Cohort Study
GM-CSF and Cytokine Storm in Coronavirus
A new role for an old cytokine: GM-CSF amplifies GVHD
Role of GM-CSF in acute GVHD
Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells
Lenzilumab Study Published in ‘blood’
Humanigen GM-CSF Review
Lenzilumab at ASH 2018 - Abstract
Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
EphA3 Publication in 'Cancers'
Hypoxia-Controlled EphA3 Marks a Human Endometrium-Derived Multipotent Mesenchymal Stromal Cell that Supports Vascular Growth
Eosinophil surface receptor EMR1: a novel therapeutic target for eosinophilic disorders